Literature DB >> 28425761

Adult pilocytic astrocytoma of conus medullaris: clinical considerations and review of the literature.

José Pedro Lavrador1,2, Edson Oliveira1, José Pimentel3, Sérgio Livraghi1,4.   

Abstract

Astrocytomas are responsible for 30% of all primitive intramedullary tumors with cervicothoracic predominance. However, only about one hundred cases of intramedullary pilocytic astrocytomas were described. The authors described the case of a 69 year-old patient presenting with a broad-base gait, bilateral pain and dysesthesia of inferior limbs with a diagnosis of an intra-axial cystic lesion centered to the conus medullaris, diagnosed as pilocytic astrocytoma of conus medullaris (PACM) after surgery. To the best of our knowledge, only two previous reports concerning PACM were made. As benign lesions associated with long survivals, function should be the mainstay of treatment of PACM. Surgical resection should be performed. Adjuvant radiotherapy or chemotherapy has no establish role in pilocytic astrocytic lesions.

Entities:  

Keywords:  chemotherapy; conus medullaris; intramedullary spinal cord tumor; pilocytic astrocytoma; radiotherapy

Mesh:

Year:  2017        PMID: 28425761      PMCID: PMC6020877          DOI: 10.2217/cns-2016-0030

Source DB:  PubMed          Journal:  CNS Oncol        ISSN: 2045-0907


  18 in total

Review 1.  Intramedullary spinal cord tumors: a review of current and future treatment strategies.

Authors:  Matthew K Tobin; Joseph R Geraghty; Herbert H Engelhard; Andreas A Linninger; Ankit I Mehta
Journal:  Neurosurg Focus       Date:  2015-08       Impact factor: 4.047

2.  Long-term survival and functional status of patients with low-grade astrocytoma of spinal cord.

Authors:  Clifford G Robinson; Richard A Prayson; Joseph F Hahn; Iain H Kalfas; Melvin D Whitfield; Shih-Yuan Lee; John H Suh
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-09-01       Impact factor: 7.038

Review 3.  Primary intramedullary tumors of the spinal cord.

Authors:  James S Harrop; Aruna Ganju; Michael Groff; Mark Bilsky
Journal:  Spine (Phila Pa 1976)       Date:  2009-10-15       Impact factor: 3.468

4.  Prognostic factors and survival in primary malignant astrocytomas of the spinal cord: a population-based analysis from 1973 to 2007.

Authors:  Hadie Adams; Javier Avendaño; Shaan M Raza; Ziya L Gokaslan; George I Jallo; Alfredo Quiñones-Hinojosa
Journal:  Spine (Phila Pa 1976)       Date:  2012-05-20       Impact factor: 3.468

5.  [Pilocytic astrocytoma of the conus medullaris].

Authors:  D Baréa; P Richez; E Gueguen; G Clavel; F Grisoli; J F Briant
Journal:  J Radiol       Date:  1999-07

6.  Analysis of risk factors and survival in pediatric high-grade spinal cord astrocytoma: a population-based study.

Authors:  Sandi Lam; Yimo Lin; Stephanie Melkonian
Journal:  Pediatr Neurosurg       Date:  2013-07-20       Impact factor: 1.162

7.  Surgical treatment of primary spinal tumors in the conus medullaris.

Authors:  In-Ho Han; Sung-Uk Kuh; Dong-Kyu Chin; Keun-Su Kim; Byung-Ho Jin; Yong-Eun Cho
Journal:  J Korean Neurosurg Soc       Date:  2008-08-30

8.  Temozolomide in pediatric low-grade glioma.

Authors:  Seong L Khaw; Lee T Coleman; Peter A Downie; John A Heath; David M Ashley
Journal:  Pediatr Blood Cancer       Date:  2007-11       Impact factor: 3.167

9.  Extent of surgical resection of malignant astrocytomas of the spinal cord: outcome analysis of 35 patients.

Authors:  Matthew J McGirt; Ira M Goldstein; Kaisorn L Chaichana; Michael E Tobias; Karl F Kothbauer; George I Jallo
Journal:  Neurosurgery       Date:  2008-07       Impact factor: 4.654

10.  Rare tumor of conus medullaris in an adult with a favorable outcome.

Authors:  Ashish Kumar; Rajan M Shah; Nimit Gupta
Journal:  J Surg Tech Case Rep       Date:  2012-01
View more
  2 in total

1.  Efficacy of surgery for the treatment of astrocytoma: A protocol of systematic review and meta-analysis.

Authors:  Guo-Wei Wang; Bao-Ming Li
Journal:  Medicine (Baltimore)       Date:  2020-06-05       Impact factor: 1.817

2.  Sterically stabilized recombined HDL composed of modified apolipoprotein A-I for efficient targeting toward glioma cells.

Authors:  Jin Li; Mengmeng Han; Jianfei Li; Zhiming Ge; Qianqian Wang; Kai Zhou; Xiaoxing Yin
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.